Genetic Disruption at the CIP2A Locus Modulates T Cell Responses and Attenuates Experimental Autoimmune Encephalomyelitis
Authors:
- Mohd Moin KhanMKMohd Moin Khan
- Inna StarskaiaISInna Starskaia
- Emilie RydgrenEREmilie Rydgren
- Sini JunttilaSJSini Junttila
- Johannes SmolanderJSJohannes Smolander
- Meraj Hasan KhanMKMeraj Hasan Khan
- Rahul BiradarRBRahul Biradar
- Roosa KattelusRKRoosa Kattelus
- Anne AhtikoskiAAAnne Ahtikoski
- Maria GardbergMGMaria Gardberg
- Mudassir Meraj BandayMBMudassir Meraj Banday
Preprint
Abstract
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS) driven by pathogenic T cell-mediated inflammation. Fingolimod (FTY720), an approved therapy for MS, is an established activator of protein phosphatase 2A (PP2A). However the contribution of PP2A in autoimmune neuroinflammation remains incompletely understood. Here, we addressed this question using experimental autoimmune encephalomyelitis (EAE), a murine model of MS, in mice carrying a genetic disruption of the locus encoding cancerous inhibitor of protein phosphatase 2A (CIP2A), an endogenous inhibitor of PP2A. Mice with disruption of the CIP2A locus, the knock out (KO) mice, exhibited attenuated EAE severity compared with wild-type (WT) controls. Histological and flow-cytometric analyses revealed markedly reduced infiltration of mononuclear cells, including CD4 + and CD4 + CXCR6 + encephalitogenic T cells, in the CNS of diseased KO mice. Reduced numbers of these T cell populations were also observed in peripheral lymphoid organs of the Cip2a-deficient mice during EAE, while T cell abundance was comparable under steady-state conditions, suggesting impaired activation-induced expansion rather than altered homeostasis or migration. Single-cell RNA sequencing of CNS and lymph node immune cells revealed changes in cell-type abundance and gene expression. Notably, Il17a expression was reduced in CNS CD8+ T cells and showed a similar trend in γδ T cells. Together, our findings reveal that genetic disruption at the CIP2A locus attenuates EAE, possibly by limiting the expansion and accumulation of encephalitogenic T cell populations in CNS. These results identify the CIP2A locus as a previously unrecognized regulator of T cell-driven autoimmune neuroinflammation and provide new insights into mechanisms that restrain pathogenic T cell responses during EAE.Keywords
Funding Information
- Finnish cancer foundation
- Novo Nordisk Fonden (NNF19OC0057218)
- Jane ja Aatos Erkon Säätiö
- European Research Council (677943)
This publication has 28 references indexed in Scilit:
- Th17 cell pathogenicity in autoimmune diseaseExperimental & Molecular Medicine, 2025
- Stem-like intestinal Th17 cells give rise to pathogenic effector T cells during autoimmunityCell, 2021
- The role of TH17 cells in multiple sclerosis: Therapeutic implicationsAutoimmunity Reviews, 2020
- CIP2A Constrains Th17 Differentiation by Modulating STAT3 SignalingiScience, 2020
- The role of CIP2A in cancer: A review and updateBiomedicine & Pharmacotherapy, 2017
- Effect of FTY720 on the SET–PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activityLeukemia, 2014
- Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A‐RIPK1‐dependent necroptosisEMBO Molecular Medicine, 2012
- Interleukin-1 and IL-23 Induce Innate IL-17 Production from γδ T Cells, Amplifying Th17 Responses and AutoimmunityImmunity, 2009
- Late Developmental Plasticity in the T Helper 17 LineageImmunity, 2009
- CIP2A Inhibits PP2A in Human MalignanciesCell, 2007